Shaping the Microglia in Retinal Degenerative Diseases Using Stem Cell Therapy: Practice and Prospects
Ni Jin1,2, Weiwei Sha2, Lixiong Gao1
1Senior Department of Ophthalmology, The Third Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Abstract:
Retinal degenerative disease (RDD) refers to a group of diseases with retinal degeneration that cause vision loss and affect people's daily lives. Various therapies have been proposed, among which stem cell therapy (SCT) holds great promise for the treatment of RDDs. Microglia are immune cells in the retina that have two activation phenotypes, namely, pro-inflammatory M1 and anti-inflammatory M2 phenotypes. These cells play an important role in the pathological progression of RDDs, especially in terms of retinal inflammation. Recent studies have extensively investigated the therapeutic potential of stem cell therapy in treating RDDs, including the immunomodulatory effects targeting microglia. In this review, we substantially summarized the characteristics of RDDs and microglia, discussed the microglial changes and phenotypic transformation of M1 microglia to M2 microglia after SCT, and proposed future directions for SCT in treating RDDs.
Insights
Stem cell therapy shows promise for retinal degenerative diseases by modulating microglia, the immune cells involved in retinal inflammation. This review explores how stem cell therapy can shift microglia from a pro-inflammatory to an anti-inflammatory state for potential treatment.
Area of Science:
- Ophthalmology
- Immunology
- Regenerative Medicine
Background:
- Retinal degenerative diseases (RDDs) cause vision loss.
- Stem cell therapy (SCT) is a promising RDD treatment.
- Microglia, retinal immune cells, influence RDD pathology via M1 (pro-inflammatory) and M2 (anti-inflammatory) phenotypes.
Purpose of the Study:
- To review RDDs and microglia characteristics.
- To discuss microglial changes and M1-to-M2 transformation post-SCT.
- To propose future directions for SCT in RDD treatment.
Main Methods:
- Literature review of RDDs and stem cell therapy.
- Analysis of microglial roles in RDDs.
- Examination of SCT's immunomodulatory effects on microglia.
Main Results:
- Microglia play a key role in RDD inflammation.
- SCT can modulate microglial phenotypes towards an M2 state.
- Evidence suggests SCT's therapeutic potential for RDDs.
Conclusions:
- SCT offers a promising therapeutic strategy for RDDs.
- Targeting microglial phenotype is crucial for SCT efficacy.
- Further research is needed to optimize SCT for RDDs.
More Related Videos
06:24Generation of Human Microglia to Combine Them with Retinal Organoids for Improved Disease Modeling
Published on: July 26, 2024
05:35Transplantation of Human Induced Pluripotent Stem Cell-Derived Microglia in Immunocompetent Mice Brain via Non-Invasive Transnasal Route
Published on: May 31, 2022
